• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Prothrombin Complex Concentrate Increases Risk of Thromboembolic Events in Trauma Patients

March 29, 2023

Four-factor prothrombin complex concentrate (4F-PCC) is a lyophilized concentrate of coagulation factors that is commonly used for urgent reversal of warfarin and other vitamin K antagonists.  4F-PCC has been used to treat coagulopathy and bleeding in cardiac surgery patients.  Recent observational studies suggest that 4F-PCC may also reduce blood product consumption for trauma patients.  In order to test this hypothesis, researchers in France randomized 327 severe trauma patients (median age, 39 years; 73% men; median Injury Severity Score, 36) to receive either 4F-PCC (N=164) or a saline placebo (N=160) immediately  after admission.  In this multi-center, double-blinded superiority trial, no differences were found for blood product consumption (red blood cells, frosh frozen plasma, and platelets) during the first 24 hours after admission (12 units in the 4F-PCC arm compared to 11 units in the placebo arm, p=0.72).  Furthermore, no differences were observed in 24-hour and 28-day mortality by treatment arm.  However, patients in the 4F-PCC arm were more likely to have a thromboembolic event compared to those in the placebo arm (35% vs. 24%; relative risk, 1.48; 95% C.I., 1.04-2.10; p=0.03).  Further research is needed to better understand trauma induced coagulopahty and the best treatments for these patients.

Reference:

Bouzat P, Charbit J, Abback P, et al. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial.  Published online March 21, 2023. doi:10.1001/jama.2023.4080  

Filed Under

  • Coagulation & Plasma Transfusion
  • News
  • Special Transfusion Situations

Recommended

  • Sexually Transmitted Disease Rates among Reinstated MSM Donors

  • Hospitalized COVID-19 Patients with Early Disease and Preexisting Conditions May Benefit from Convalescent Plasma

  • Red Blood Cells Stored for More Than 35 Days are Safe

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley